Dermata Therapeutics- Warrants (13/08/2026) Total Current Liabilities

The latest total current liabilities for DRMAW is $1.1M as of March 2026. That compares with $1.4M in the prior-year period — down 24.6% year over year. Investors often review this figure alongside Dermata Therapeutics- Warrants (13/08/2026)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, DRMAW's total current liabilities moved from $1.4M to $1.1M — a 24.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Dermata Therapeutics- Warrants (13/08/2026)'s operating scale or balance-sheet position.

A total current liabilities figure of $1.1M for DRMAW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting DRMAW's total current liabilities ($1.1M), review year-over-year change from $1.4M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Dermata Therapeutics- Warrants (13/08/2026)'s total current liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.